Phenobarbital and its Sodium Salt - IARC Monographs on the ...

More documents

Recommendations

Info

Table 3 (contd) Strain (sex) Initiator, dose, route <strong>and</strong> duration Fischer 344 (M) Fischer 344 (M <strong>and</strong> F) NDEA, 1 × 100 mg/kg bw (day 1) + MNU, 4 × 20 mg/kg bw (days 2, 5, 8, 11), ip + NBHPA, 0.1% in water, 2 weeks (weeks 3–4) NDEA, 10 mg/kg bw × 1 (24 h after PH) at 4 weeks, 6 or 12 months of age, ig Wistar (F) NDEA, 10 mg/kg bw, ig Fischer 344 (M) Fischer 344/DuCrj (M) NBHPA, 1000 mg/kg bw × 2 (week 1), ip; NEHEA, 1500 mg/kg bw × 2 (week 2), ip; DMAB, 75 mg/kg bw (week 3), sc × 2 NDEA, 100 mg/kg bw, ip Interval between initiator <strong>and</strong> promoter Dose <strong>and</strong> duration of PB or NaPB <strong>and</strong> route 0 day NaPB, 0.05% diet, 14 or 20 weeks Promoting or anti-promoting effects on preneoplastic or neoplastic hepatocellular lesions GST-P-positive foci; increase in number <strong>and</strong> size of foci 2 weeks PB, 0.05%, 6 months γ-GT-positive foci; growth more effective at 6 months than when initiated at 4 weeks or 12 months; males more susceptible 10 days PB, 20, 50, 100, 200 <strong>and</strong> 200 mg/L in water for 70, 23, 11, 9, 5 weeks, respectively ATPase-deficient foci; not increased at 20 mg/L; no effect at 50, 100 mg/L; inhibitory effect at 200 mg/L 1 week PB, 0.05% diet, 12 weeks GST-P-positive foci; promotion by PB 1 week PB, 1, 4, 16, 75, 300 or 1200 mg/L in water, 39 weeks γ-GT-positive, GST-P-positive foci; dose-dependent promotion by PB from 75 to 1200 mg/L Reference Shibata et al. (1990) Xu et al. (1990) Appel et al. (1991) Uwagawa et al. (1992) Maekawa et al. (1992) 192 <strong>IARC</strong> MONOGRAPHS VOLUME 79
Table 3 (contd) Strain (sex) Initiator, dose, route <strong>and</strong> duration SPF Wistar (M/F) Fischer 344 (M) Fischer 344 (M) Sprague- Dawley (F) AFB 1, 2 mg/kg bw (M), 5 mg/kg bw (F), ig PB, 0.1% in water, AFB 1, 1 mg/kg bw, ip NBHPA, 2000 mg/kg bw, sc Interval between initiator <strong>and</strong> promoter Dose <strong>and</strong> duration of PB or NaPB <strong>and</strong> route 3 weeks PB, 50 mg/kg diet for 70 weeks (F) <strong>and</strong> 55–59 weeks (M) Promoting or anti-promoting effects on preneoplastic or neoplastic hepatocellular lesions GST subun<strong>its</strong>; mostly eosinophilic clear-cell foci with elevated levels of mu (Yb1, Yb2) <strong>and</strong> pi (Yp) family subun<strong>its</strong> – PB, 1 week before AFB 1 GST-P-positive foci; inhibition of AFB 1-induced foci by PB 1 week PB, 1000 mg/kg bw or (PB, 500 mg/kg bw diet + thiourea, 0.05% in water), 19 weeks NDEA, 10 mg/kg bw 1 week PB, 500 mg/kg diet for 170 or 240 days; + TCDD (150 μg/kg diet) from 170 to 240 days or 240 to 450 days Wistar (M) Tamoxifen, 420 mg/kg diet, 3 months Fischer 344 (M) Sprague- Dawley (F) 0 days PB, 0.1% in water for 3, 6, 9, 12 months or lifetime 192 Ir seeds None PB, 0.05% diet, 20, 40 or 60 weeks NDEA, 10 mg/kg bw, ip at 5 days of age 16 days PB, 10, 100 or 500 mg/kg diet <strong>and</strong>/or mestranol, 0.02 or 0.2 mg/kg diet, 8 months Eosinophilic, basophilic, clear-cell foci; increase with PB; synergistic with thiourea Eosinophilic foci; PB alone, no effect; PB + TCDD, increase in number <strong>and</strong> size GST-P-positive foci; increased at 6 <strong>and</strong> 9 months PB promoted development of EAIs initiated by 192 Ir GST-P-positive foci; growth at low mestranol + 10 or 100 mg/kg diet PB; no growth at low mestranol + 500 mg/kg diet PB; high mestranol effective only with 100 mg/kg diet PB Reference Grasl-Kraupp et al. (1993) Gopalan et al. (1993) Shimo et al. (1994) Sills et al. (1994) Carthew et al. (1995) Ida et al. (1995) Dragan et al. (1996) PHENOBARBITAL AND ITS SODIUM SALT 193
Page 1 and 2: PHENOBARBITAL AND ITS SODIUM SALT T
Page 3 and 4: (b) Spectroscopy data: Infrared [pr
Page 5 and 6: Republic of Iran, Japan, the Philip
Page 7 and 8: Table 1. Cohort studies of cancer i
Page 9 and 10: Table 1 (contd) Country (reference)
Page 11 and 12: PHENOBARBITAL AND ITS SODIUM SALT 1
Page 15 and 16: Table 2. Case-control studies of ba
Page 17 and 18: Table 2 (contd) Country (reference)
Page 25 and 26: 3.3 Administration with known carci
Page 27 and 28: Table 3 (contd) Strain (sex) Initia
Page 31: Table 3 (contd) Strain (sex) Initia
Page 37 and 38: Table 4. Promotion of thyroid tumou
Page 43 and 44: Table 5 (contd) DMBA, 7,12-dimethyl
Page 57 and 58: diet or diet containing 0.05% pheno
Page 79 and 80: In a review of exposure to anti-epi
Page 83 and 84:
educed throughout life. Serum testo
Page 85 and 86:
PHENOBARBITAL AND ITS SODIUM SALT 2
Page 87 and 88:
in CYP1A2 expression was also seen.
Page 89 and 90:
Table 6 (contd) Test system Result
Page 91 and 92:
Table 6 (contd) Test system Result
Page 93 and 94:
Table 6 (contd) Test system Inhibit
Page 95 and 96:
Table 6 (contd) Test system Inhibit
Page 97 and 98:
Page 99 and 100:
these tumours was a CG → AT trans
Page 101 and 102:
5. Summary of Data Reported <strong
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
show all

Phenobarbital and its Sodium Salt - IARC Monographs on the ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?